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INTRODUCTION: Little is known about the consequences of the carbohydrate enriched diet 
used to treat patients with Phenylketonuria (PKU) in terms of obesity and metabolic syndrome 
(MetSyn) development.  
OBJECTIVES: Our study aimed to investigate the prevalence of overweight and obesity, and its 
consequences in terms of body composition and MetSyn in early treated patients with PKU 
compared to controls.  
MATERIAL AND METHODS: A sample of 89 patients with PKU (3-30y; 14.4±6.6y) and 79 
controls (3-47y; 16.3±7.9y) were studied. In the fasted state, anthropometric, body 
composition, blood pressure and analytical parameters [amino acids, glucose, insulin, total and 
HDL-cholesterol (HDL-c), triglycerides (TG), high sensitivity c-reactive protein and uric acid] 
were performed. Data on dietary intake was collected. Body mass index was classified using 
WHO criteria, while the definition from International Diabetes Federation (IDF) was used for 
MetSyn.    
RESULTS: Prevalence of overweight and obesity (32.6% vs. 24.1%; p=0.293), body fat 
percentage (22% vs. 23.1%, p=0.581) and central obesity (36.9% vs. 36.4%, p=0.999) were 
comparable to controls. Patients revealed a higher TG/HDL-c (p<0.001). The prevalence of 
MetSyn was 1.5% and 6.1% in patients and controls, respectively.  
CONCLUSIONS: Patients and controls were similar in terms of overweight and obesity, body 
composition and MetSyn. However, the dyslipidemia in patients with PKU in relation to 
overweight and obesity may help us trying to understand the course and the etiology of 
MetSyn not only in PKU but also in the general population. 
